A Multi-Center, Randomized, Double-Blind, Placebo-Controlled Study of the Human Anti-TNF Monoclonal Antibody Adalimumab for the Maintenance of Clinical Remission in Subjects With Crohn's Disease
收藏DataCite Commons2025-07-24 更新2026-05-07 收录
下载链接：
https://search.vivli.org/doiLanding/studies/00002950/isLanding
下载链接
链接失效反馈官方服务：
资源简介：
The objectives were: (1) To demonstrate the efficacy of adalimumab in the maintenance of clinical remission up to 56 weeks in participants with Crohn's disease who participated in NCT00055523; (2) To delineate the safety of adalimumab when administered to participants with Crohn's disease up to 56 weeks.
提供机构：
Vivli
创建时间：
2018-10-27
